X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of SBP-101 (ivospemin), which is designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 01, 2024
Details:
The net proceeds will be used for the development of SBP-101 (ivospemin), which is designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
The company intends to use the net proceeds for the clinical development of SBP-101 (ivospemin), which is designed to induce polyamine metabolic inhibition (PMI) for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
SBP-101 (ivospemin) is a small molecule AMD1/ODC1 inhibitor. It is being evaluated in phase 2/3 clinical trials in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
CPP-1X-T (eflornithine) is a single agent tablet or high dose powder sachet for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset type 1 diabetes. It is approved by USFDA for the treatment of Pediatric Neuroblastoma.
Lead Product(s): Eflornithine
Therapeutic Area: Oncology Product Name: CPP-1X-T
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: US WorldMeds
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
SBP-101 (ivospemin) is a small molecule AMD1/ODC1 inhibitor. It is being evaluated in phase 3 clinical trials in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
SBP-101 (ivospemin) is a polyamine analogue designed to induce polyamine metabolic inhibition by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
Panbela has divested certain assets in its eflornithine pediatric neuroblastoma program including, CPP-1X (eflornithine), being developed for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.
Lead Product(s): Eflornithine
Therapeutic Area: Oncology Product Name: CPP-1X
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: US WorldMeds
Deal Size: $9.5 million Upfront Cash: Undisclosed
Deal Type: Divestment July 19, 2023
Details:
SBP-101 (ivospemin) is a polyamine analogue designed to induce polyamine metabolic inhibition by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
The Company intends to use the net proceeds for the continued clinical development of its product candidates including, SBP-101 (diethyl dihydroxyhomospermine), a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI).
Lead Product(s): Diethyl Dihydroxyhomospermine,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 21, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
